HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Evidence that plaque can shrink: CENIT, PRECISE-IVUS, ZEUS, EVAPORATE and GLAGOV

Louis Nervegna · Jun 25, 2025 · ♥ 72 reactions · 42 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugsExercise & fitness
AI summary & key facts

Post by group member Daniel Chong summarising trials showing plaque change: supervised HIIT in CENIT, ezetimibe in PRECISE-IVUS, ezetimibe added to statin in ZEUS, icosapent ethyl in EVAPORATE and evolocumab in GLAGOV. It notes some research suggests a 1% reduction in plaque volume may equate to a 20% reduction in event risk.

This excellent post is written by our group member Daniel Chong.

Also see this link below for strategies rigorously proven to reverse plaque in randomized controlled trials: ↪ Six strategies shown to regress plaque in human randomized trials

#reverseHD #exerciseHD #hiitHD #pavHD #ezetimibeHD #statinsHD #epaHD #omega3HD #fishoilHD #pcsk9HD #nattokinaseHD #ornishHD #esselstynHD #colchicineHD #ldlHD #supplementsHD #statinreverseHD

Research cited

IS THERE EVIDENCE THAT PLAQUE CAN SHRINK?

This is an important question considering the fact that some research shows even just a 1% reduction in plaque volume may equate to a 20% reduction in risk for cardiovascular event.

The evidence below also helps confirm that there is more than one way to do it, as long as we are working on the mechanisms that underlie it....

1- EXERCISE
CENIT Trial (2022)
Supervised HIIT (High-Intensity Interval Training)
Percent volume of plaque (PAV) shrank −1.2% per year
Control group? No change.

2- EZETIMIBE (a non-statin LDL lowering drug)
PRECISE-IVUS Trial (2015)
PAV dropped −1.4%
78% of patients showed regression

3- ADDITIVE EFFECTS OF DRUGS
ZEUS Trial (2014)
In diabetic ACS patients, adding Ezetimibe shrunk plaque by 13.9% vs 5.1% with statin alone.
The lower you go with LDL the more plaque may shrink.

4- HIGH DOSE EPA
EVAPORATE Trial (2020)
EPA (Icosapent Ethyl, 4g/day)
−17% in vulnerable plaque
KEY- The plaque didn't shrink much, but the type of plaque did. This suggests many things that help reduce inflammation and oxidative stress in the vascular lining, including even just intensive diet changes, may help similarly. Adding treatments from different angles will likely have an even stronger effect.

5- PCSK9 INHIBITORS
GLAGOV Trial (2016)
Evolocumab (PCSK9i)
PAV dropped −0.63%/year
Note- This is an LDL lowering drug that works totally differently than statins or ezetimibe, but it still achieved similar effects. Why? Because if you lower LDL enough, however you do it, it will help shrink plaque.

6- STATINS
SATURN Trial (2011)
Rosuvastatin
PAV dropped −0.42% to −0.50% per year
More statin = more LDL lowering = more plaque shrinkage

7- STATINS
ASTEROID Trial (2006)
Rosuvastatin 40mg (high dose)
PAV dropped −0.49%/year

8- NATTOKINASE
A clinical study involving 1,062 participants found that daily supplementation with 10,800 FU of nattokinase over 12 months led to significant reductions in carotid artery plaque size and thickness.
PLEASE NOTE- There was NO CONTROL GROUP so this was not a high quality study. It does, however, raise very interesting questions especially considering how safe nattokinase appears to be when taken correctly.

9- COLCHICINE
EKSTROM trial adding colchicine to statins
Colchicine is anti-inflammatory
PAV reduced by −1.1% in 1 year
So no change in LDL here, just inflammation control, and more benefit seen.

10- LIFESTYLE MEDICINE
The Ornish Lifestyle Heart Trial
Randomized controlled trial
Treatment group did the following for 5 yrs:
-Very low fat, whole food vegetarian diet
-Group counseling
-Aerobic exercise
-Smoking cessation
-Stress management practice
1.75% decrease in blockage (stenosis) after 1 yr and 3.1% after 5 yrs in treatment group. (control group all got worse)

LAST BUT NOT LEAST:
Whatever treatment choices you make, DON'T ASSUME YOU ARE GOOD. Test and don't guess, to make sure!

(for anyone wondering- I did not include Dr Esselstyn's research bc they did not specifically measure plaque regression as one of the outcomes for the study)

(thnx to Tro Kalayjian for gathering this info)

No photo description available.
← newer: Six strategies proven to reverse plaque in human RCTsolder: Treating midlife hearing loss may reduce dementia risk; up t →